Importantly, treatment with NOS/NMDA-R inhibitors (L-NAME and ketamine) attenuated the negative effects of MS on autistic-like behaviors, decreased nitrite levels, and suppressed the expression of iNOS, nNOS, NR2A, and NR2B genes in the hippocampus. Here, GRIN2B is linked to myeloid sarcoma.